Your heart will no longer need to work in overdrive, and the palpitations should start to ease up
Rather than flooding your system with hormones, peptides encourage your body to produce what it needs naturally
Ensuring absolute accuracy prevents overlapping charges and maintains strict adherence to federal healthcare compliance standards
Phase 2 trial data (Jastreboff et al., NEJM 2023) demonstrated average weight reductions of approximately 1724% over 48 weeks notably higher than currently approved GLP-1 receptor agonists such as semaglutide, though direct comparisons are limited by differences in trial populations and designs
However, every treatment has some downsides
Integrating genetic predisposition data with biomarker assessment (B12 status, homocysteine, liver function, carnitine) and your clinical history enables a more informed conversation with your provider about whether MIC B12, oral supplements, GLP-1 peptide therapy, or multimodal metabolic support is most appropriate for your individual situation